Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis

  • FDA approval for Cosentyx® is based on the Phase III PREVENT trial,  demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial spondyloarthritis (axSpA) disease spectrum
     
  • There are an estimated 2.7M people living with axial spondyloarthritis (axSpA) in the US; however, it remains significantly underdiagnosed1,2
     
  • nr-axSpA approval is the fourth indication for Cosentyx, which is backed by five years of clinical data supporting …
/by